Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(17)
•••
Post by antisenseon Oct 18, 2018 12:39pm
128 Views
Post# 28828183

Bio Investor presentation new INFO

Bio Investor presentation new INFOThe investor conference presentation is already posted on the BIO investor website.  The below link shoudl take you to the recording.

https://www.veracast.com/webcasts/bio/investorforum2018/

The new info listed by IMV indicates that the Merck prelim results on Ovarian trial are now set for END of 2018. There is also a new milestone listed for END of 2018 regarding meeting with the FDA to accelerate registration trials for ovarian and DBCL. See slide 16 of presentation.

GLTA
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities